Utility of GnRH-agonists for fertility preservation in women with operable breast cancer: Is it protective?

被引：19

作者：

Bedoschi G. ^{[1
,2
]}

Turan V. ^{[1
,2
]}

Oktay K. ^{[1
,2
]}

机构：

[1] Laboratory of Molecular Reproduction and Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, NY

[2] Innovation Institute for Fertility Preservation, IVF, New York, NY 10028

来源：

Current Breast Cancer Reports | 2013年 / 5卷 / 4期

关键词：

Breast cancer; Chemotherapy; Clinical trials; Fertility preservation; GnRH agonist; Gonadal damage; Gonadal suppression;

D O I：

10.1007/s12609-013-0123-y

中图分类号：

学科分类号：

摘要：

Breast cancer is the most common type of malignancy in reproductive-age women. Breast cancer chemotherapy is associated with premature ovarian failure, infertility, and negative psychosocial effects related to these reproductive changes. As a result of this, fertility preservation becomes highly critical in this group of women. Besides the fertility preservation methods that utilize assisted reproductive technologies such as embryo, oocyte, and ovarian tissue cryopreservation, another suggested strategy for fertility preservation is suppression of ovarian ovulatory function by gonadotropin-releasing hormone agonist (GnRHa) administration before and during chemotherapy. However, both the efficacy and safety of GnRH agonists for prevention of ovarian damage are unproven and the preponderance of evidence indicates that this is an ineffective strategy. This review details the most recent information and studies on this controversial topic. © 2013 Springer Science+Business Media New York.

引用

页码：302 / 308

页数：6

共 42 条

[21]

Glode L.M., Robinson J., Gould S.F., Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone, Lancet, 1, 8230, pp. 1132-1134, (1981)

[22]

Sy Ortin T.T., Shostak C.A., Donaldson S.S., Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: The Stanford Experience, International Journal of Radiation Oncology Biology Physics, 19, 4, pp. 873-880, (1990)

[23]

Blumenfeld Z., How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries, Oncologist, 12, 9, pp. 1044-1054, (2007)

[24]

Kitajima Y., Endo T., Nagasawa K., Manase K., Honnma H., Baba T., Hayashi T., Chiba H., Sawada N., Saito T., Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5, Endocrinology, 147, 2, pp. 694-699, (2006)

[25]

Grundker C., Emons G., Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer, Reproductive Biology and Endocrinology, 1, (2003)

[26]

Morita Y., Perez G.I., Paris F., Et al., Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy, Nat Med, 6, pp. 1109-1114, (2000)

[27]

Oktay K., Sonmezer M., Oktem O., Fox K., Emons G., Bang H., Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury, Oncologist, 12, 9, pp. 1055-1066, (2007)

[28]

Waxman J.H., Ahmed R., Smith D., Failure to preserve fertility in patients with Hodgkin's disease, Cancer Chemotherapy and Pharmacology, 19, 2, pp. 159-162, (1987)

[29]

Leung P.C.K., Cheng C.K., Zhu X.-M., Multi-factorial role of GnRH-I and GnRH-II in the human ovary, Molecular and Cellular Endocrinology, 202, 1-2, pp. 145-153, (2003)

[30]

Cheng C.K., Leung P.C., Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans, Endocr Rev, 26, pp. 283-306, (2005)

← 1 2 3 4 5 →